7,480 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Nears 52-Week High

Options Event and Cash Market Price Action

The call option contracts traded on Sun Pharmaceutical Industries Ltd are set to expire imminently on 30 Jun 2026, indicating a short-term directional wager. The Rs 1,900 strike price is marginally above the current stock price of Rs 1,889.80, placing these calls slightly out-of-the-money (OTM). However, given the proximity to the underlying price, these options carry significant gamma sensitivity, implying that small price movements in the stock could substantially affect option values. The turnover for these contracts was approximately ₹124.88 lakhs, reflecting robust trading interest.

Meanwhile, the stock outperformed its sector by 0.41% on the day, gaining 1.50%, and remains close to its 52-week high of Rs 1,916.60. This price action aligns with the surge in call activity, suggesting that the derivatives market is echoing the underlying momentum rather than diverging from it — does this alignment signal sustained momentum or a near-term peak?

Strike Price and Moneyness Analysis

The Rs 1,900 strike calls are positioned just above the current market price, categorising them as slightly out-of-the-money. This strike selection typically indicates a speculative upside bet, where traders anticipate the stock will breach this level before expiry. The closeness of the strike to the underlying price suggests that the market participants are not merely betting on distant targets but are focused on near-term gains. Such positioning often reflects confidence in a continuation of the recent upward trend, especially with expiry just a day away.

Given the stock’s proximity to its 52-week high, these calls could be viewed as a tactical play to capitalise on a potential breakout or sustained rally — is this a signal of imminent upside or a last push before resistance?

Open Interest and Contracts Analysis

The open interest (OI) at the Rs 1,900 strike stands at 4,665 contracts, while the number of contracts traded on the day was 7,480. This results in a contracts-to-OI ratio of approximately 1.6:1, which is relatively high and indicative of fresh positioning rather than mere rotation of existing holdings. Such a ratio suggests that new money is entering the call options at this strike, reinforcing the notion of a directional bet rather than hedging or profit-taking.

High turnover combined with a sizeable open interest near expiry points to a concentrated short-term wager on the stock’s upside. This dynamic is particularly noteworthy given the stock’s recent price strength and proximity to key resistance levels — does this fresh positioning foreshadow a breakout or a volatile expiry session?

Cash Market Context and Moving Averages

Sun Pharmaceutical Industries Ltd is trading comfortably above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong bullish trend across multiple timeframes. This technical backdrop supports the directional call activity, as the stock’s momentum appears intact. The 1.50% gain on the day further confirms the positive price action, which is consistent with the fresh call buying at the Rs 1,900 strike.

However, delivery volumes tell a slightly different story. On 25 Jun, delivery volume was 11.11 lakh shares, down 13.1% against the 5-day average, indicating a decline in investor participation in the cash market. This divergence between rising call activity and falling delivery volumes suggests that while derivatives traders are positioning for upside, the cash market participation is somewhat subdued — is this a sign of cautious optimism or a potential disconnect between cash and derivatives?

Delivery Volume and Liquidity

The stock remains liquid, with a trade size capacity of approximately ₹7.59 crore based on 2% of the 5-day average traded value. This liquidity supports active trading in both cash and derivatives segments, allowing for efficient price discovery. The falling delivery volume, however, may indicate that some investors are opting to express their views through options rather than outright stock purchases, possibly due to capital efficiency or risk management considerations.

Key Data at a Glance

Conclusion: What the Options and Cash Data Signal

The surge in call contracts at the Rs 1,900 strike, combined with a contracts-to-OI ratio above 1.5, points to fresh, near-term bullish positioning in Sun Pharmaceutical Industries Ltd. The proximity of the strike to the current price and the imminent expiry date underscore the urgency and conviction behind this directional bet. The stock’s strong technical positioning above key moving averages and its closeness to the 52-week high lend further credence to this momentum.

However, the decline in delivery volumes amid rising call activity introduces a note of caution, suggesting that while derivatives traders are optimistic, cash market participation is more restrained. This divergence raises the question of whether the options market is leading the cash market or if the rally is approaching a critical juncture — buy, sell, or hold Sun Pharmaceutical Industries Ltd given this mixed signal?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today